Cargando…

The impact of peroxisome proliferator‐activated receptor‐γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy

BACKGROUND: Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte‐mediated antitumor activity. METHODS: We conducted a ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Cho‐Han, Chang, Yu‐Cheng, Wang, Shih‐Syuan, Chen, Yuan‐Jen, See, Xin Ya, Peng, Chun‐Yu, Hsia, Yuan Ping, Chiang, Cho‐Hsien, Chiang, Cho‐Hung, Peng, Cheng‐Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	BRIEF COMMUNICATION
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166924/ https://www.ncbi.nlm.nih.gov/pubmed/36825549 http://dx.doi.org/10.1002/cam4.5734

Ejemplares similares

Angiotensin Converting-Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers Are Associated with Prolonged Vascular Access Patency in Uremic Patients Undergoing Hemodialysis
por: Chen, Fu-An, et al.
Publicado: (2016)

Effects of corticosteroids on severe community-acquired pneumonia: a closer look at the evidence
por: Chiang, Cho-Han, et al.
Publicado: (2023)

Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study
por: Wu, Hon-Yen, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma
por: Hsu, Hui-Tzu, et al.
Publicado: (2016)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptor-γ in Thyroid Autoimmunity
por: Ferrari, Silvia Martina, et al.
Publicado: (2015)

Activation of peroxisome proliferator-activated receptor γ inhibits vascular calcification by upregulating Klotho
por: Cheng, Lijuan, et al.
Publicado: (2017)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator
por: Hamano, Yuki, et al.
Publicado: (2011)

Combination of a peroxisome proliferator‐activated receptor‐gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats
por: Shim, Chi Young, et al.
Publicado: (2013)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
por: Cho, Min Ae, et al.
Publicado: (2020)

Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation
por: Ohshima, Kousei, et al.
Publicado: (2012)

Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis
por: Liu, Huang-Jun, et al.
Publicado: (2016)

Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases
por: Zhang, Su, et al.
Publicado: (2015)

Effect of peroxisome proliferator-activated receptor γ on inflammatory markers
por: Khazaei, Majid
Publicado: (2015)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Sequence Variants of Peroxisome Proliferator-Activated Receptor-Gamma Gene and the Clinical Courses of Patients with End-Stage Renal Disease
por: Chao, Chia-Ter, et al.
Publicado: (2015)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Apoptotic Mechanisms of Peroxisome Proliferator–Activated Receptor-γ Activation in Acinar Cells During Acute Pancreatitis
por: Xu, Ping, et al.
Publicado: (2016)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
por: Alexander, Stephen PH, et al.
Publicado: (2012)

Antifibrotic effect by activation of peroxisome proliferator-activated receptor–γ in corneal fibroblasts
por: Pan, Hongwei, et al.
Publicado: (2009)

Peroxisome Proliferator-Activated Receptor γ Activity is Required for Appropriate Cardiomyocyte Differentiation
por: Peymani, Maryam, et al.
Publicado: (2016)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders
por: Cho, Min-Chul, et al.
Publicado: (2008)

Peroxisome proliferator-activated receptor-γ as the gatekeeper of tight junction in Clostridioides difficile infection
por: Lai, Yi-Hsin, et al.
Publicado: (2022)

Severe Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations
por: Kim, Da-Rae, et al.
Publicado: (2013)

Impact of peroxisome proliferator-activated receptor γ on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice
por: Tiyerili, Vedat, et al.
Publicado: (2015)

New Target Genes for the Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Antitumour Activity: Perspectives from the Insulin Receptor
por: Foti, Daniela P., et al.
Publicado: (2009)

Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
por: Żółkiewicz, Jakub, et al.
Publicado: (2019)

Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea
por: Jung, Mi‐Hyang, et al.
Publicado: (2021)

Maintaining mask stockpiles in the COVID-19 pandemic: Taiwan as a learning model
por: Chiang, Cho-Hung, et al.
Publicado: (2020)

Letter to editor - Can universal masking help with our recovery from the COVID-19 pandemic?
por: Chiang, Cho-Hung, et al.
Publicado: (2020)

Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
por: Lee, Su Jin, et al.
Publicado: (2021)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3id1t8dacv7mj2c7qbcvrku3ar